Abstract
Objective To examine humoral and cellular response in multiple sclerosis patients on anti-CD20 therapy after third BNT162b2 mRNA SARS-CoV-2 vaccination.
Methods A prospective longitudinal study design from first throughout third vaccination in Danish and American MS centers. All participants were treated with ocrelizumab. Antibody (Ab) levels were assessed before and after third vaccination using SARS-CoV-2 IgG II Quant assay (Abbott Laboratories). B- and T-lymphocytes enumeration was done with BD Multitest™6-color TBNK reagent. Spike-specific T-cell responses were measured through PBMC stimulation with spike peptide pools (JPT Peptide Technologies).
Results We found that 14.0%, 37.7%, and 33.3% were seropositive after first, second and third vaccination. The median Ab-levels were 74.2 BAU/mL (range: 8.5-2427), 43.7 BAU/ml (range: 7.8-366.1) and 31.3 BAU/mL (range: 7.9-507.0) after first, second and third vaccination, respectively. No difference was found in levels after second and third vaccination (p=0.1475). Seropositivity dropped to 25.0% of participants before the third vaccination, a relative reduction of 33.3% (p=0.0020). No difference was found between frequencies of spike reactive CD4+ and CD8+ T-cells after second (0.65 ± 0.08% and 0.95 ± 0.20%, respectively) and third vaccination (0.99 ± 0.22% and 1.3 ± 0.34%), respectively.
Conclusion In this longitudinal cohort we found no significant increased humoral or cellular response with administration of a third SARS-CoV-2 mRNA vaccination. These findings suggest the need for clinical strategies to include allowance of B cell reconstitution before repeat vaccination and/or provision of pre-exposure prophylactic monoclonal antibodies.
What is already known on this topic Studies have described decreased humoral response and sustained T-cell reactivity after standard two-dose SARS-CoV-2 mRNA vaccination during anti-CD20 therapy in multiple sclerosis participants.
What this study adds Persistently decreased humoral, but stable cellular reactivity following a third SARS-CoV-2 mRNA vaccination.
How this study might affect research, practice or policy The findings suggest the need for clinical strategies to include allowance of B cell reconstitution before repeat vaccination and/or provision of pre-exposure prophylactic monoclonal antibodies.
Competing Interest Statement
H Bajwa, F Novak, A C Nilsson, KE Byg, I S Johansen, C Nielsen, D K Holm, A B Jacobsen, K Mittl, and W Rowles have nothing to disclose.
J Sabatino has received research support from Novartis.
R Bove has received research support from Biogen, Roche Genentech, and Novartis. She has received personal consulting fees from Alexion, Biogen, EMD Serono, Novartis, Roche Genentech, and Sanofi Genentech. She is funded by Harry Weaver Award from the National Multiple Sclerosis Society and the National Institutes of Health.
SS Zamvil has received consulting honoraria from Alexion, Biogen-Idec, EMD-Serono, Genzyme, Novartis, Roche/Genentech, and Teva Pharmaceuticals, Inc and has served on Data Safety Monitoring Boards for Lilly, BioMS, Teva, and Therapeutics.
T Sejbaek has received travel grants from Biogen, Merck, Novartis, and Roche, has received research grants from Biogen and has served on advisory boards for Biogen, Merck, and Novartis.
Funding Statement
This study was conducted with fundings from Danish Neurological Society, Lundbeck and Roche.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Danish study followed national laws adhering to good clinical practice and was approved by the Danish National Committee on Health Research Ethics (Protocol no. S 20200068C) and Danish Data Protection Agency (journal no. 20/19,878).
The study conducted by UCSF was made with the approval of the institutional review board (University of California, San Francisco, Committee on Human Research, protocol #21 33240).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Pre-graduate fellow H. M. Bajwa, Dr. Novak, & Dr. Sejbaek conducted the statistical analysis and graphical presentations in collaboration.
Data Availability
Anonymized data will be shared on request from any qualified investigator under approval from the Danish Data Protection Agency.
